Advertisement Deals Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Deals

March 9, 2020

AbbVie receives marketing authorisation from EC to shorten MAVIRET duration for treatment-naïve genotype 3 HCV patients with compensated cirrhosis

AbbVie said that the European Commission has approved a change to the marketing authorization for MAVIRET (glecaprevir/pibrentasvir) to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT) 3 infection.

AbbVie receives marketing authorisation from EC to shorten MAVIRET duration for treatment-naïve genotype 3 HCV patients with compensated cirrhosis